New genes identified for fibromuscular dysplasia

Genetic meta-analysis helps researchers detect genes related to this cardiovascular disease that affects mostly women and defines relationships to other more common cardiovascular conditions.

5:00 AM

Author | Haley Otman

image of drawing of gene in blue ink on lined paper with lab note written on bottom right
Michigan Medicine

Three new genetic variants that regulate gene expression in the arteries are connected to fibromuscular dysplasia, an arterial disease that can cause dangerous consequences for the heart and vessels, according to a new study.

The findings, published in Nature Communications by an international team of FMD experts from the United States and Europe, also confirmed the importance of a fourth genetic target that has already been identified as involved with the disease.

"We once thought FMD was a rare disease, but the current estimate is that it may affect more than 3% of the population," said co-senior and co-corresponding author Santhi Ganesh, M.D., an associate professor of internal medicine and human genetics, and a cardiologist at the University of Michigan Health Frankel Cardiovascular Center. "It's vital that we continue this research to better understand what causes FMD. The disease primarily affects women in the prime of their lives, and the diagnosis often comes after a dangerous cardiovascular complication such as severe high blood pressure, a stroke, or a heart attack."

Researchers note the genes identified suggest that the genetic basis of FMD may contribute through altered vascular smooth muscle cell structure and function.

Notably, the genetic findings pointed to a correlation with several more common cardiovascular diseases that are often reported in tandem with FMD, including high blood pressure, migraine headache, intracranial aneurysm and subarachnoid hemorrhage. There was a negative correlation to atherosclerotic coronary artery disease, while no shared genetics were confirmed with ischemic stroke, which also commonly affects people with FMD.

"The findings provide new biologic insights into this intriguing condition and genes and pathways to study further, toward the goal of identifying therapeutic targets for FMD," said co-senior and co-corresponding author Nabila Bouatia-Naji, Ph.D., director of research at France's Institut National de la Santé et de la Recherche Médicale, also known as INSERM and team leader at the Paris Cardiovascular Research Center.

Ganesh and Bouatia-Naji's team combed through data from genome-wide association studies of more than 1,500 FMD cases, comparing them to more than 7,000 control samples from participants without FMD. The three new genes implicated for FMD are ATP2B1, LRP1 and LIMA1, while the fourth that was confirmed is known as PHACTR1.

"This is the most comprehensive genetic investigation of FMD to date, and was made possible through the collective efforts of our international research teams," Ganesh noted.

Paper cited: "Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases," Nature Communications. DOI: 10.1038/s41467-021-26174-2

SEE ALSO: Uncovering the Genetics Behind Heart Attacks That Surprise Young, Healthy Women


More Articles About:

Lab Notes Heart disease Heart Disease in Women Genetic Disorders Genetic Testing Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

A man sits on a large red tractor. Behind him a bunch of corn is stacked in the back of the vehicle
Health Lab

Michigan man undergoes complex heart repair after last minute surgery cancelation

A complex operation at U-M Health enabled surgeons to remove scar tissue surrounding Scott Roach's heart and successfully repair his failing mitral valve.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.
Computer screens and microscope pictured in a laboratory setting.
Health Lab

Understanding family history key to early detection of pancreatic cancer

How genetic testing and family history help identify individuals at high risk for pancreatic cancer, enabling earlier screening and better treatment outcomes.
Michael Powers pictured here holding a fish he caught as he stands in a boat. He struggled with pancreatitis for several decades and found answers at University of Michigan Health.
Health Lab

Patient with rare form of diabetes finds answers in genetic testing, clinical trials

Discover how genetic testing and a groundbreaking clinical trial helped one man overcome rare hyperchylomicronemia, high triglycerides, and pancreatitis.